Singapore-based firm on track to commercialise cancer drug
Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020
Singapore
SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.
A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.
TRENDING NOW
Prima to move out of historic Keppel Road flour mill building in 2028
Grab CEO’s wife Chloe Tong on life with Anthony Tan and finding her purpose
OCBC sheds S$8 billion in value as shares close nearly 6% down; analysts cautious on banks
As Asia’s food delivery giants rejig the pie, who will win the market?
